Transitional cell metaplasia of fallopian tube fimbriae: A potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women with BRCA mutations

American Journal of Surgical Pathology

Volumn 33, Issue 1, 2009, Pages 111-119

  Rabban, Joseph T ^a   Crawford, Beth ^c   Chen, Lee May ^b   Powell, Catherine B ^b   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA; Early tubal carcinoma; Risk reducing salpingo oophorectomy; Transitional cell metaplasia

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORPHOLOGY; CANCER RISK; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FIMBRIA; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; METAPLASIA; MITOSIS; ONCOGENE; OVARY CANCER; PROTEIN EXPRESSION; RISK REDUCTION; SALPINGOOOPHORECTOMY; STAINING; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; UTERINE TUBE CARCINOMA; DIFFERENTIAL DIAGNOSIS; GENETIC PREDISPOSITION; METABOLISM; MIDDLE AGED; MUTATION; OVARIECTOMY; PATHOLOGY; RISK FACTOR; TUMOR SUPPRESSOR GENE; UTERINE TUBE; UTERINE TUBE TUMOR;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; METAPLASIA; MIDDLE AGED; OVARIECTOMY; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59149103323     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31817d74a7     Document Type: Article

References (50)

1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
2. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
3. Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophor-ectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40.
4. Colgan TJ. Challenges in the early diagnosis and staging of fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol. 2003;22:109-120.
5. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25:1283-1289.
6. Crome L. Squamous metaplasia of the peritoneum. J Pathol Bacteriol. 1950;62:61-68.
7. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44.
8. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7:223-229.
9. Egan AJ, Russell P. Transitional (urothelial) cell metaplasia of the fallopian tube mucosa: morphological assessment of three cases. Int J Gynecol Pathol. 1996;15:72-76.
10. Egan AJ, Russell P. Transitional (urothelial) cell metaplasia of the uterine cervix: morphological assessment of 31 cases. Int J Gynecol Pathol. 1997;16:89-98.
11. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
12. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
13. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24:4642-4660.
14. Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol (R Coll Radiol). 2000;12:58-59.
15. Hunt JL, Lynn AA. Histologic features of surgically removed fallopian tubes. Arch Pathol Lab Med. 2002;126:951-955.
16. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927.
17. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
18. Kim JW, Cho EM, Kim YT, et al. A case of primary transitional cell carcinoma of the fallopian tube. J Obstet Gynaecol Res. 1999;25: 321-326.
19. Koshiyama M, Konishi I, Yoshida M, et al. Transitional cell carcinoma of the fallopian tube: a light and electron microscopic study. Int J Gynecol Pathol. 1994;13:175-180.
20. Laki F, Kirova YM, This P, et al. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109:1784-1790.
21. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159-162.
22. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13:1-7.
23. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35.
24. Leunen K, Legius E, Moerman P, et al. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer. 2006;16:183-188.
25. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18:2728-2732.
26. Lynch HT, Lemon SJ, Durham C, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 1997;79:2219-2228.
27. McCluggage WG. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology. 2007;39:97-111.
28. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
29. Mourra N, Nion I, Parc R, et al. Squamous metaplasia of the peritoneum: a potential diagnostic pitfall. Histopathology. 2004;44: 621-622.
30. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Breast Cancer Risk Reduct. 2007. Available at: http://www.nccn.org. Accessed May 16, 2008.
31. Olivier RI, van BM, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90:1492-1497.
32. Paner GP, Gonzalez M, Al-Masri H, et al. Parafallopian tube transitional cell carcinoma. Gynecol Oncol. 2002;86:379-383.
33. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
34. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005; 23:127-132.
35. Rabczynski JK, Kochman AT. Primary cancer of the fallopian tube with transitional differentiation. Clinical and pathological assessment of 6 cases. Neoplasma. 1999;46:128-131.
36. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
37. Roth LM. The Brenner tumor and the Walthard cell nest. An electron microscopic study. Lab Invest. 1974;31:15-23.
38. Rutgers JL, Scully RE. Cysts (cystadenomas) and tumors of the rete ovarii. Int J Gynecol Pathol. 1988;7:330-342.
39. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003;95:1072-1078.
40. Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 1996;88: 1810-1820.
41. Sauramo H. Development, occurrence, function and pathology of the rete ovarii. Acta Obstet Gynecol Scand Suppl. 1954;33:29-46.
42. Schatz JE, Colgan TJ. Squamous metaplasia of the peritoneum. Arch Pathol Lab Med. 1991;115:397-398.
43. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
44. Takeuchi S, Hirano H, Ichio T, et al. A case report: rare case of primary transitional cell carcinoma of the fallopian tube. J Obstet Gynaecol Res. 1999;25:29-32.
45. Teoh TB. The structure and development of Walthard nests. J Pathol Bacteriol. 1953;66:433-439.
46. Uehira K, Hashimoto H, Tsuneyoshi M, et al. Transitional cell carcinoma pattern in primary carcinoma of the fallopian tube. Cancer. 1993;72:2447-2456.
47. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72:367-379.
48. Walthard M. Zur aetiologie der ovarialadenome. Zeitschr Geburts Gynäk. 1903;49:233.
49. Weir MM, Bell DA, Young RH. Transitional cell metaplasia of the uterine cervix and vagina: an underrecognized lesion that may be confused with high-grade dysplasia. A report of 59 cases. Am J Surg Pathol. 1997;21:510-517.
50. Young RH. Neoplasms of the fallopian tube and broad ligament: a selective survey including historical perspective and emphasising recent developments. Pathology. 2007;39:112-124.